A groundbreaking discovery by researchers at the Technical University of Munich has revealed a novel mechanism that could revolutionize the treatment of multiple myeloma. This research highlights how an established cancer drug, carfilzomib, can be utilized to reactivate immunotherapy, offering new hope to patients with advanced multiple myeloma. The study, published in a renowned scientific journal, uncovers the role of the ubiquitin-proteasome system in the disappearance of BCMA, a molecule crucial for CAR-T cell therapies. This finding not only sheds light on the underlying mechanisms of multiple myeloma but also opens up exciting possibilities for enhancing the effectiveness of immunotherapy.
